Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BRCA2 (Breast cancer 2, early onset)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FoundationOne® CDx (110)

Guardant360® CDx (54)

BRACAnalysis CDx™ (28)

FoundationOne® Liquid CDx (21)

Myriad myChoice® CDx (19)

FoundationOne® Heme CDx (10)

TruSight Oncology 500 Assay (3)

AmoyDx® HRD Focus Panel (2)

FoundationFocus CDxBRCA Assay (2)

Guardant360 TissueNext™ (2)

Tempus xT Assay (1)

23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)

AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit

AmoyDx® BRCA Pro Panel

AmoyDx® HANDLE HRR NGS Panel

AmoyDx® HRD Complete Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer™ VARIANTPlex™ Complete Solid Tumor panel

Archer™ VARIANTPlex™ Pan Solid Tumor panel

AVENIO ctDNA Expanded Kit

AVENIO ctDNA Surveillance Kit

AVENIO ctDNA Targeted Kit

AVENIO Tumor Tissue Expanded Kit

AVENIO Tumor Tissue Surveillance Kit

AVENIO Tumor Tissue Targeted Kit

Aventa FusionPlus Test

Blueprint Genetics Comprehensive Hereditary Cancer Panel

BRCAaccuTest PLUS

BRCA MASTR Plus Dx

BRCAvantage™ Plus

BROCA Cancer Risk Panel

CancerNext-Expanded®

CNV+ Breast Cancer NGS Panel

Color’s Hereditary Cancer Tes

Counsyl Reliant™ Cancer Screen

CustomNext-Cancer®

Devyser BRCA NGS

Devyser BRCA PALB2 NGS

Devyser HBOC NGS

Empower™ Hereditary cancer test

GALEAS™ Hereditary Plus

GeneseeqPrime™HRD

geneType Breast Cancer Risk Assessment Test

Guardant360® Liquid

Invitae Common Hereditary Cancers Panel

Labcorp® Plasma Complete™

LiquidHALLMARK®

Myriad myRisk® Hereditary Cancer

Myriapod® NGS BRCA1-2 panel

NeXT Dx™ Test

Northstar Select™

NovoFocus™ PARPi CDx

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

Oncomine™ BRCA Research Assay

Oncomine™ Comprehensive Assay Plus

OncoPanel™ Assay

oncoReveal™ 4-Gene Methylation Panel

OncoReveal™ BRCA1 & BRCA2 plus CNV Panel

OptiSeq™ BRCA1 and BRCA2 Panel

OptiSeq™ Pan-Cancer Gene Panel

PanTracer™ Tissue + HRD

PGDx elio™ plasma resolve assay

SOPHiA DDM HRD Solution

StrataNGS™ Test

SureSeq™ Germline Breast Cancer + CNV Panel

Tempus xF Assay

Tempus xF+ Panel

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

FoundationOne® CDx (110)

Guardant360® CDx (54)

BRACAnalysis CDx™ (28)

FoundationOne® Liquid CDx (21)

Myriad myChoice® CDx (19)

FoundationOne® Heme CDx (10)

TruSight Oncology 500 Assay (3)

AmoyDx® HRD Focus Panel (2)

FoundationFocus CDxBRCA Assay (2)

Guardant360 TissueNext™ (2)

Tempus xT Assay (1)

23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)

AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit

AmoyDx® BRCA Pro Panel

AmoyDx® HANDLE HRR NGS Panel

AmoyDx® HRD Complete Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer™ VARIANTPlex™ Complete Solid Tumor panel

Archer™ VARIANTPlex™ Pan Solid Tumor panel

AVENIO ctDNA Expanded Kit

AVENIO ctDNA Surveillance Kit

AVENIO ctDNA Targeted Kit

AVENIO Tumor Tissue Expanded Kit

AVENIO Tumor Tissue Surveillance Kit

AVENIO Tumor Tissue Targeted Kit

Aventa FusionPlus Test

Blueprint Genetics Comprehensive Hereditary Cancer Panel

BRCAaccuTest PLUS

BRCA MASTR Plus Dx

BRCAvantage™ Plus

BROCA Cancer Risk Panel

CancerNext-Expanded®

CNV+ Breast Cancer NGS Panel

Color’s Hereditary Cancer Tes

Counsyl Reliant™ Cancer Screen

CustomNext-Cancer®

Devyser BRCA NGS

Devyser BRCA PALB2 NGS

Devyser HBOC NGS

Empower™ Hereditary cancer test

GALEAS™ Hereditary Plus

GeneseeqPrime™HRD

geneType Breast Cancer Risk Assessment Test

Guardant360® Liquid

Invitae Common Hereditary Cancers Panel

Labcorp® Plasma Complete™

LiquidHALLMARK®

Myriad myRisk® Hereditary Cancer

Myriapod® NGS BRCA1-2 panel

NeXT Dx™ Test

Northstar Select™

NovoFocus™ PARPi CDx

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

Oncomine™ BRCA Research Assay

Oncomine™ Comprehensive Assay Plus

OncoPanel™ Assay

oncoReveal™ 4-Gene Methylation Panel

OncoReveal™ BRCA1 & BRCA2 plus CNV Panel

OptiSeq™ BRCA1 and BRCA2 Panel

OptiSeq™ Pan-Cancer Gene Panel

PanTracer™ Tissue + HRD

PGDx elio™ plasma resolve assay

SOPHiA DDM HRD Solution

StrataNGS™ Test

SureSeq™ Germline Breast Cancer + CNV Panel

Tempus xF Assay

Tempus xF+ Panel

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

›

BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1